Olanzapine and haloperidol for residual symptoms

Am J Psychiatry. 2005 Jul;162(7):1392-3; author reply 1393. doi: 10.1176/appi.ajp.162.7.1392.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Ambulatory Care
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacokinetics
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / pharmacokinetics
  • Benzodiazepines / therapeutic use*
  • Dose-Response Relationship, Drug
  • Haloperidol / administration & dosage
  • Haloperidol / pharmacokinetics
  • Haloperidol / therapeutic use*
  • Humans
  • Olanzapine
  • Receptors, Dopamine D2 / metabolism
  • Research Design / standards
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine D2
  • Benzodiazepines
  • Haloperidol
  • Olanzapine